[A discussion of the methods for the assessment of chronic hepatitis B-related liver fibrosis regression].
Antiviral therapy could reverse hepatitis B-related liver fibrosis and early-stage cirrhosis. However, the assessment of fibrosis regression remains controversial. As the gold standard for assessment, liver biopsy has its own limitations. In terms of non-invasive assessment, there are many interfering factors for transient elastography and less clinical evidence for the use of serum markers. Therefore, further evidence from clinical studies is still needed to determine the role of non-invasive methods in evaluating fibrosis regression.